Form 4: Madrigal Pharmaceuticals Executive Rebecca Taub Reports Stock Sales

Rebecca Taub, a key executive at Madrigal Pharmaceuticals, executed multiple sales of company stock between April 3rd and April 5th, 2024, while also exercising stock options.

Summary

• Rebecca Taub, President of R&D and CMO at Madrigal Pharmaceuticals, reported multiple transactions involving the company's common stock.
• Between April 3rd and April 5th, 2024, Taub exercised stock options to acquire a total of 73,888 shares at a price of $9.45 per share.
• Concurrently, Taub sold a portion of her holdings in multiple transactions at varying prices, ranging from approximately $239.57 to $248.23 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2023.
• Following these transactions, Taub directly owns 458,999 shares of common stock and indirectly owns 655,540 shares through SQN LLC.
• She also holds options to purchase 79,240 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive. The transactions themselves don't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects, although sales can be driven by various personal financial planning reasons.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment if interpreted as a lack of confidence by the executive, although the pre-planned nature of the sales mitigates this concern.

Key Dates